Knight Ptb Ratio from 2010 to 2024

GUD Stock  CAD 5.67  0.07  1.25%   
Knight Therapeutics PTB Ratio yearly trend continues to be very stable with very little volatility. PTB Ratio is likely to drop to 0.71. PTB Ratio is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on Knight Therapeutics' equity relative to its net asset value. View All Fundamentals
 
PTB Ratio  
First Reported
2010-12-31
Previous Quarter
0.74678013
Current Value
0.71
Quarterly Volatility
100.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Knight Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Knight Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 75.6 M, Interest Expense of 9.4 M or Selling General Administrative of 87.9 M, as well as many indicators such as Price To Sales Ratio of 1.61, Dividend Yield of 0.5 or PTB Ratio of 0.71. Knight financial statements analysis is a perfect complement when working with Knight Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Knight Therapeutics Technical models . Check out the analysis of Knight Therapeutics Correlation against competitors.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Knight Stock

Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.